Physician profile
Doris E Tirado
NPI 1386655512
$470.10
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $115 · 2021: $29.83 · 2022: $42.40.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $86.85 | 2019-2020 | |
| Abbvie INC. | $84.11 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $72.90 | 2019 | |
| Amgen INC. | $53.68 | 2019 | |
| Mylan Pharmaceuticals INC. | $32.75 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.57 | 2019-2022 | |
| Medtronic, INC. | $23.61 | 2022 | |
| Therapeuticsmd, INC. | $19.93 | 2019 | |
| Allergan, INC. | $17.79 | 2019 | |
| Pfizer INC. | $17.41 | 2021 | |
| Kci USA, INC. | $15.60 | 2020 | |
| Avion Pharmaceuticals | $14.90 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Tirado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.